How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Neurodegenerative therapy: Vector(s) containing an inducible gene encoding a cell cycle regulator useful for treating neurodegenerative disorders.

Organization name

GWT-TUD GmbH

Profile

The present invention provides a vector containing a gene useful for treating neurodegenerative disorders, especially Alzheimer’s disease. These vectors can be used in therapeutic applications to prevent neurodegenerative disorders or to slow down their progression with therapeutic efficacy.

The Medical Problem

In our aging society, a still growing number of patients suffer from age-associated CNS-disorders. Neurodegenerative disorders, namely Alzheimer’s disease (AD) and stroke giving rise to vascular dementia (VD) are most prominent. By 2025 about one-third of the European population will be older than 65 years and, thus, be at high risk for AD, stroke and VD. Stroke is the most common neurologic disease and the leading cause of adult disability. Both morbidity and mortality of stroke sharply rise with increasing age. Next to stroke, AD is the second leading cause of adult disability, and represents the fastest growing area of unmet medical need.

The Solution

AD and stroke share a cell death pathway that is activated by unscheduled neuronal cell cycle re-entry and subsequent partial replication of DNA. Moreover, the selective cell death of neurones which have replicated their DNA could be shown in AD recently. This directly proofs the link between cell cycle activation and cell death in neurons of the adult human central nervous system (CNS) and identifies the molecular control of cell cycle activation as therapeutic target.

Features

  • Therapeutic concept of neuroprotection by neuron-specific targeting of cell cycle
  • Neuroprotective effects had been proven on in vivo models of ischemic cell death and excitotoxicity mimicking the effects ofAß.
  • High therapeutic efficacy and minimal or no side-effects
  • Anticipation to bring these therapeutic tools in a joined effort to a first clinical application within a framework of five years

Application

  • AD or stroke will be in the direct focus of the first therapeutic application
  • Approach will also be applicable to other neurodegenerative disorders and non-neuronal disorders with unscheduled cellcycle activation, such as cancer or atherosclerosis

patent pending: EP2218784A1 and US200120004277A1

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries